Novartis
NVS
NVS
1,201 hedge funds and large institutions have $14.9B invested in Novartis in 2023 Q2 according to their latest regulatory filings, with 98 funds opening new positions, 341 increasing their positions, 476 reducing their positions, and 68 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
1.03% less ownership
Funds ownership: 7.54% → 6.52% (-1%)
7% less funds holding in top 10
Funds holding in top 10: 14 → 13 (-1)
28% less repeat investments, than reductions
Existing positions increased: 341 | Existing positions reduced: 476
Holders
1,201
Holding in Top 10
13
Calls
$677M
Puts
$292M
Top Buyers
| 1 | +$67.9M | |
| 2 | +$65.7M | |
| 3 | +$39.7M | |
| 4 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$33.3M |
| 5 |
D.E. Shaw & Co
New York
|
+$26.7M |
Top Sellers
| 1 | -$716M | |
| 2 | -$394M | |
| 3 | -$263M | |
| 4 |
Goldman Sachs
New York
|
-$176M |
| 5 |
Primecap Management
Pasadena,
California
|
-$143M |